专业：药理学
导师：硕士生导师
个人简历
2018-至今，副教授，中山医学院，中山大学
2015-2018：博士后，中山大学
2010-2015：博士研究生，药理学专业，中山大学
2006-2010：本科生，生物技术与应用专业，中山大学
?
研究方向
??????? 溶瘤病毒疗法（Oncolytic Virotherapy）是一种靶向治疗、免疫治疗和基因治疗相结合的新兴抗肿瘤疗法。我们主要从事新型溶瘤病毒的基础和应用基础研究，研究方向主要包括：
1. 基于合成生物学技术的溶瘤病毒工程化改造；
2. 溶瘤病毒靶向肿瘤和杀伤肿瘤的分子机制研究；
3. 免疫系统在溶瘤病毒疗法中的“双刃剑”机制研究。
?
主要学术研究成果
2018年在《Nat Commun》以共同通讯作者报道溶瘤病毒M1靶向RHOQ缺陷肿瘤。
2018年在《Nat Commun》以共同通讯作者报道靶向抑制DNA-PK增效溶瘤病毒M1。
2017年在《Sci Transl Med》以共同第一作者报道靶向抑制ERAD通路增效溶瘤病毒M1。
2017年在《PNAS》以共同第一作者报道溶瘤病毒M1引起肿瘤细胞“内斗”。
2014年在《PNAS》以第一作者报道溶瘤病毒M1靶向ZAP缺陷肿瘤。
?
学术论著
1.?? ?Lin Y, Zhang H, Liang J, Li K, Zhu W, Fu L, Wang F, Zheng X, Shi H, Wu S, Xiao X, Chen L, Tang L, Yan M, Yang X, Tan Y, Qiu P, Huang Y, Yin W, Su X, Hu H, Hu J, Yan G. Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. Proc Natl Acad Sci U S A. 2014, 111:E4504-4512.
2.?? ?Zhang H, Li K, Lin Y (co-first author), Xing F, Xiao X, Cai J, Zhu W, Liang J, Tan Y, Fu L, Wang F, Yin W, Lu B, Qiu P, Su X, Gong S, Bai X, Hu J, Yan G. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Sci Transl Med. 2017, 9:eaam7996.（Nature Reviews Gastroenterology & Hepatology发表对本文的科学评述文章）
3.?? ?Cai J, Lin Y (co-first author), Zhang H, Liang J, Tan Y, Cavenee WK, Yan G. Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics. Proc Natl Acad Sci U S A. 2017, 114:6812-6817.
4.?? ?Wu S, Lin Y (co-first author), Xu D, Chen J, Shu M, Zhou Y, Zhu W, Su X, Zhou Y, Qiu P, Yan G. MiR-135a functions as a selective killer of malignant glioma. Oncogene, 2012, 31:3866-3874.
5.?? ?Zhang H, Lin Y (co-first author), Li K, Liang J, Xiao X, Cai J, Tan Y, Xing F, Mai J, Li Y, Chen W, Sheng L, Gu J, Zhu W, Yin W, Qiu P, Su X, Lu B, Tian X, Liu J, Lu W, Dou Y, Huang Y, Hu B, Kang Z, Gao G, Mao Z, Cheng SY, Lu L, Bai XT, Gong S, Yan G, Hu J. Naturally existing oncolytic virus M1 is nonpathogenic for the nonhuman primates after multiple rounds of repeated intravenous injections. Hum Gene Ther. 2016, 27:700-711.
6.?? ?Tan Y, Lin Y (co-first author), Li K, Xiao X, Liang J, Cai J, Guo L, Li C, Zhu W, Xing F, Mai J, Gu J, Tan X, Yin W, Lu B, Qiu P, Su X, Gao M, Hu J, He S, Lu L, Gong S, Yan G, Zhang H. Selective antagonism of Bcl-xL potentiates M1 oncolysis by enhancing mitochondrial apoptosis. Hum Gene Ther. 2018, 29(8):950-961.
7.?? ?Liang J, Li K, Xiao X, Zhu W, Zheng X, Hu J, Zhang H, Cai J, Tan Y, Li C, Yu Y, Hu C, Liu Y, Qiu P, Su X, He S, Guo L, Liu X, Lin Y (co-corresponding author), Yan G. Inhibition of the Mevalonate pathway enhances cancer cell oncolysis mediated by M1 Virus. Nat Commun, 2018, 9(1):1524.
8.?? ?Xiao X, Liang J, Huang C, Li K, Xing F, Zhu W, Lin Z, Xu W, Wu G, Zhang J, Lin X, Tan Y, Cai J, Hu J, Chen X, Huang Y, Qin Z, Qiu P, Su X, Chen L, Lin Y (co-corresponding author), Zhang H, Yan G. DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage. Nat Commun, 2018, 9(1):4342.
9.?? ?Li K, Hu C, Xing F, Gao M, Liang J, Xiao X, Cai J, Tan Y, Hu J, Zhu W, Yin W, Li Y, Chen W, Lu B, Mai J, Qiu P, Su X, Yan G, Zhang H, and Lin Y (corresponding author). Deficiency of the IRE1α-autophagy axis enhances the antitumor effects of the oncolytic virus M1. J Virol, 2018, 92(6). pii: e01331-17.